RFI - GEIS Network Illumina Sequencing Platform Modernization

The Defense Health Agency's Global Emerging Infections Surveillance (GEIS) Branch has issued a Request for Information (RFI) to assess the commercial availability of next-generation sequencing systems capable of replacing legacy Illumina sequencers across 18 laboratory sites worldwide. The RFI seeks information specifically regarding Illumina MiSeq i100 Plus sequencing instruments equipped with integrated DRAGEN onboard analysis capabilities, room-temperature stable reagents, and comprehensive support services. Key requirements include delivery and support capabilities at designated CONUS and OCONUS locations spanning Japan, South Korea, Guam, Thailand, Germany, Peru, Kenya, Georgia, Ghana, and Singapore; new MiSeq i100 Plus systems with standard components and proprietary DRAGEN technology; on-site installation with operational qualification and personnel training; annual Silver service contracts including preventative maintenance, emergency repairs, software updates, and remote support; full availability of room-temperature stable sequencing reagents and consumables; and the ability to maintain favorable Authority to Operate decisions under the Risk Management Framework. Respondents must submit information electronically in Microsoft Word or PDF format by May 29, 2026, at 8:00 A.M. EST to Jeffrey Sprecher, Contract Specialist, at jeffrey.b.sprecher.civ@health.mil, and responses should include organizational details, completed attachments, and sufficient technical data demonstrating compliance with all stated requirements.

This is an unclassified set-aside procurement with no established incumbents or current contractors identified in the RFI. Respondents must provide company information including DUNS number, SAM registration status, small business certification, availability on federal procurement vehicles such as CHESS, GSA, and NASA SEWP, Trade Agreements Act compliance, manufacturing location, customer references, and estimated annual maintenance costs. No specific award value or budget range has been disclosed in the RFI, and the notice emphasizes that responses submitted are not offers and will not be returned, nor will evaluation letters be issued to respondents. The RFI does not constitute a solicitation, and potential offerors are advised to monitor for the release of a formal solicitation in the future. The government is conducting this RFI to determine market feasibility before proceeding to a full competitive acquisition.